Zevra to net $150M from priority review voucher sale tied to Miplyffa approval
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that keeps on giving. | After receiving a rare pediatric disease priority review voucher in tandem with Miplyffa’s FDA green light in September,
Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.
The priority review voucher awarded alongside the approval of Miplyffa will be sold for $150 million, Zevra announced Thursday. The buyer of the voucher was not disclosed. Celebration, Florida ...
Zevra Therapeutics, Inc. announced that it will receive a 2025 New Treatment Award for its product MIPLYFFA™ (arimoclomol) at the 21st Annual WORLDSymposium. Eight abstracts related to MIPLYFFA ...
Zevra Therapeutics (ZVRA) has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback